Investigating genetic changes in cord blood from childhood leukemia patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect and analyze banked cord blood samples from children diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). The research focuses on backtracking the genomic alterations present in these patients to identify the origins of leukemogenic mutations that may have occurred in utero. By characterizing pre-leukemic cells, the study seeks to develop a population-wide test for detecting circulating pre-leukemia. The study involves patient recruitment through the COG Project:EveryChild and requires stored diagnostic samples for analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient must have a diagnosis of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
* Stored diagnostic pre-treatment samples corresponding to the patient's original diagnosis of leukemia must be available for request from either the COG Biopathology Center or a treating institution
* The patient must be enrolled on APEC14B1 with consent to future contact and indicate that cord blood was stored at birth in the APEC14B1 registry intake data.
* The patient must also have been registered with COG by a North American (limited to the U.S. and Canada) member institution.
* ≤ 25 years old at the time of original diagnosis with ALL or AML
* The patient must be able to understand written and spoken English or Spanish
* All patients must provide their consent/assent, as appropriate, and for patients under the age of majority at least one parent or legal guardian must provide consent as well
* All institutional, FDA, and NCI requirements for human studies must be met

Exclusion Criteria:

* Patients who responded that cord blood was not stored at birth are excluded. Patients without stored diagnostic, pre-treatment leukemia samples at either the COG Biopathology Center or their treating institution are excluded.

Where it's running

• University of Minnesota/Masonic Cancer Center
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Study coordinator: Adam de Smith, PhD
• Email: adesmith@coh.org
• Phone: (626) 218-4913

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• CD19-targeted CAR-T cells that make p40 for relapsed or refractory CD19-positive blood cancers

  This trial will try a patient's own CD19-directed CAR-T cells engineered to produce p40 to see if they work better and last longer in adults with relapsed or refractory CD19-positive blood cancers.

  Recruiting Phase 1/2 Shenzhen University General Hospital · Shenzhen, Other (Non U.s.) · NCT07584889

• Revumenib with Mezigdomide for relapsed or refractory acute leukemia

  This trial will test whether combining revumenib and mezigdomide is safe for people aged 12 and older with relapsed or refractory acute leukemia that has KMT2A, NUP98, or NPM1 genetic changes.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Duarte, California and 9 other locations · NCT07356154

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Efficacy and safety of TmBU conditioning for high-risk leukemia patients

  This study is testing a new treatment approach for high-risk leukemia patients to see if it helps them stay cancer-free after a stem cell transplant better than the current method.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06816134

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.